Specialty drugs administered in clinical settings, are quietly becoming one of the largest, least-controlled cost drivers in self-funded health plans. Unlike pharmacy benefit spend, medical specialty drugs often sit outside traditional PBM formularies and rebate channels, leaving plan sponsors with limited visibility and even less negotiating leverage.
Join Mercer and Leap for a candid, educational session on what's actually driving medical specialty spend, where the visibility and contracting gaps are hiding in your plan today, and the practical levers, from site-of-care steering to specialty pharmacy partnerships, that benefits leaders can use to take back control.
This is not a product pitch. It's a working session for HR benefits Leaders, CFOs, and Consultants who want a clearer picture of where plan dollars are going before the next renewal conversation.
You will leave with:
- A clear breakdown of how drugs end up on the medical vs. pharmacy benefit, and why that placement matters more than most plans realize
- The specific reasons medical specialty spend is harder to control: limited PBM tools, pricing variability, and dramatic cost swings by site of care
- How manufacturers build their commercialization strategy for infusion to be competitive for the provider & in the market
- The most common visibility, contracting, and utilization management gaps Mercer sees across self-funded employers
- Practical, near-term actions to regain control: line-level reporting, contracting levers, site-of-care steering, and integrated case management
- A real-world look at how dedicated infusion care coordination changes outcomes and cost from the member's first call forward
